alectinib: Clinical Trials

18 trials of alectinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 3 recruiting, 2 active not recruiting, 2 terminated. 18 Phase 1, 10 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 118Completed 10, Recruiting 3, Active not recruiting 2, Terminated 2, Not yet recruiting 1
Phase 210Completed 3, Active not recruiting 2, Recruiting 2, Terminated 2, Not yet recruiting 1

Follow alectinib: new trials by email Literature Review of alectinib trials Research Report on alectinib

Trials (filtered) newest first · largest first

All 18 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)
Alectinib - Bone Cancer
Phase 1 / Phase 2Not yet recruitingChina Medical University Hospital102026-05-152026-05-11
A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
Alectinib, Duvelisib - Anaplastic Lymphoma Kinase, Anaplastic Large Cell Lymphoma
Phase 1RecruitingMemorial Sloan Kettering Cancer Center302025-08-082026-05-26
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
Alectinib, Stereotactic Radiosurgery - Lung Cancer, NSCLC
Phase 1 / Phase 2RecruitingJoshua Palmer562024-03-072026-04-08
Alectinib Pharmacokinetic in Patients With NSCLC
Alectinib Oral Product - Non-small Cell Lung Cancer Stage IIIB, ALK Gene Mutation
Phase 1 / Phase 2RecruitingInstituto Nacional de Cancerologia de Mexico452022-05-012026-04-08
Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1
Alectinib (Alecensa), Nivolumab (Opdivo) - Hepatocellular Carcinoma
Phase 1CompletedChina Medical University Hospital52022-02-162026-03-19
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
Alectinib - ALK Fusion-positive Solid or CNS Tumors
Phase 1 / Phase 2Active not recruitingHoffmann-La Roche422021-09-142026-11-12
NCT Neuro Master Match - N²M² (NOA-20)
APG101, Alectinib, Idasanutlin - Glioblastoma, Adult
Phase 1 / Phase 2CompletedUniversity Hospital Heidelberg2282018-05-072023-09-28
A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC
Alectinib, Cobimetinib - Non-small Cell Lung Cancer
Phase 1 / Phase 2Active not recruitingMassachusetts General Hospital162017-09-142026-05-08
A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
Alectinib - ALK-positive Non-small Cell Lung Cancer (NSCLC), RET-positive Non-small Cell Lung Cancer (NSCLC)
Phase 1 / Phase 2TerminatedDana-Farber Cancer Institute52017-06-192021-09-27
Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
Alectinib - Hepatic Impairment
Phase 1CompletedHoffmann-La Roche282015-12-042018-08-24
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
Alectinib, Bevacizumab - Non-Small Cell Lung Cancer (NSCLC)
Phase 1 / Phase 2TerminatedMassachusetts General Hospital112015-09-282025-05-13
A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)
Alectinib, Atezolizumab, Erlotinib - Non-Small Cell Lung Cancer
Phase 1CompletedHoffmann-La Roche522014-04-032020-04-21
A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers
Alectinib, Posaconazole - Healthy Volunteer
Phase 1CompletedHoffmann-La Roche232013-12-012016-10-11
A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.
Alectinib, Esomeprazole, High Fat and Calorie Meal - Healthy Volunteer
Phase 1CompletedHoffmann-La Roche422013-12-012016-10-07
A Study of the Elimination, Pharmacokinetics, and Metabolism of RO5424802
RO5424802 - Healthy Volunteer
Phase 1CompletedHoffmann-La Roche62013-11-012016-11-02
A Study of the Effect of Multiple Doses of Rifampin on the Single Dose Pharmacokinetics of RO5424802
RO5424802, rifampin - Healthy Volunteer
Phase 1CompletedHoffmann-La Roche242013-10-012016-12-21
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
Alectinib - Non-Small Cell Lung Cancer
Phase 1 / Phase 2CompletedHoffmann-La Roche1342013-09-302018-08-21
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
Erlotinib, Alectinib - Non-Small-Cell Lung Carcinoma
Phase 1 / Phase 2CompletedHoffmann-La Roche1382013-06-202018-11-02

Conditions studied

Carcinoma, Non-Small-Cell Lung (7)  ·  Brain Neoplasms (2)  ·  Lung Neoplasms (2)  ·  Bone Neoplasms (1)  ·  Carcinoma, Hepatocellular (1)  ·  Central Nervous System Neoplasms (1)  ·  Glioblastoma (1)  ·  Lymphoma, Large-Cell, Anaplastic (1)  ·  Thyroid Neoplasms (1)

Sponsors

Hoffmann-La Roche (9)  ·  China Medical University Hospital (2)  ·  Massachusetts General Hospital (2)  ·  Dana-Farber Cancer Institute (1)  ·  Instituto Nacional de Cancerologia de Mexico (1)  ·  Joshua Palmer (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  University Hospital Heidelberg (1)

Countries

United States (12)  ·  France (3)  ·  South Korea (3)  ·  Spain (3)  ·  Taiwan (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Canada (2)  ·  Denmark (2)  ·  Germany (2)  ·  Italy (2)  ·  Netherlands (2)  ·  Belgium (1)  ·  Brazil (1)  ·  China (1)

Top investigators

Chang-Fang Chiu, Ph.D. (1)  ·  Ibiayi T Dagogo-Jack, MD (1)  ·  Joshua D Palmer, MD (1)  ·  Justin Gainor, MD (1)  ·  Mark Awad, MD (1)  ·  Oscar G Arrieta Rodriguez, M.D., M.Sc. (1)  ·  Robert Stuver, MD (1)  ·  Wolfgang Wick, Prof. Dr. (1)

Results publications

PMID 27863201, PMID 29748847, PMID 31706099, PMID 25153538, PMID 26708155, PMID 27130468, PMID 30052269, PMID 32009824, PMID 40913172, PMID 41213248

NIH funding

2015 (2)